- Home
- TDF vs FENC Comparison
TDF vs FENC Comparison
Compare TDF & FENC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TDF | FENC |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | Singapore | United States |
| Employees | N/A | 35 |
| Industry | Finance/Investors Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 280.0M | 230.8M |
| IPO Year | N/A | 2010 |
Fundamental Metrics
Financial Performance| Metric | TDF | FENC |
|---|---|---|
| Price | $11.21 | $6.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $14.50 |
| AVG Volume (30 Days) | 49.1K | ★ 126.2K |
| Earning Date | 01-01-0001 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $44,642,000.00 |
| Revenue This Year | N/A | $65.12 |
| Revenue Next Year | N/A | $41.08 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.09 | $5.65 |
| 52 Week High | $12.20 | $9.92 |
Technical Indicators
Market Signals| Indicator | TDF | FENC |
|---|---|---|
| Relative Strength Index (RSI) | 52.16 | 50.65 |
| Support Level | $11.01 | $5.65 |
| Resistance Level | $11.41 | $8.09 |
| Average True Range (ATR) | 0.25 | 0.33 |
| MACD | -0.01 | 0.05 |
| Stochastic Oscillator | 33.75 | 58.71 |
Price Performance
Historical ComparisonAbout TDF Templeton Dragon Fund Inc.
Templeton Dragon Fund Inc is a closed-end management investment company. The fund seeks long-term capital appreciation by investing majority of its total assets in equity securities of China companies. It invest in various sectors such as gas & consumable fuels, auto components, banks, beverages, communications equipment, healthcare equipment & supplies, restaurants & leisure, household durables and many others.
About FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.